ENXTPA:SANPharmaceuticals
Sanofi Rare Disease Pipeline Advances With Venglustat And Rezurock Progress
Sanofi (ENXTPA:SAN) reported positive Phase 3 results for its investigational oral therapy venglustat in neurological symptoms of type 3 Gaucher disease.
The company plans global regulatory filings for venglustat following these data.
Rezurock received a positive conditional recommendation for approval in Europe for chronic graft versus host disease after a previous negative opinion was reversed.
For you as an investor, these updates sit at the core of what Sanofi focuses on: treatments for...